Compare Global E Online Ltd (GLBE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Neurocrine Biosciences Inc — how do they compare? Global E Online Ltd trades at $40.39 (market cap $6.75B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GLBE | NBIX | |
|---|---|---|
Market Cap | $6.75B | $14.36B |
Volume | 1,468,708 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $185.50 |
52-Week Low | $27.54 | $123.10 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $6.24B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.15, up 3.05% today, with a bullish technical setup supported by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year 2026 outlook. Revenue grew 39% year-over-year, and adjusted EBITDA margin expanded to 20.9%. Recent news includes the appointment of a new Chief Revenue Officer and significant insider selling by executives.
The outlook is positive, driven by robust revenue growth and margin expansion, with a consensus price target of $48.86 implying 22% upside. Risks include high valuation multiples and recent insider selling. Analyst consensus is strongly bullish with 14 buy ratings, but investors should monitor competitive pressures and execution of growth initiatives.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
